Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

459.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
62 63 Next >
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda 
Via Benzinga
3 Stocks to Buy in the Booming Field of Gene Editing
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts
Via Benzinga
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend
These winners seem likely to keep up their winning ways. 
Via The Motley Fool
Topics Stocks
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Via Benzinga
Is Vertex Pharmaceuticals Stock a Buy Now?
The biotech's prospects keep improving. 
Via The Motley Fool
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
The Ultimate Growth Stock to Buy With $1,000 Right Now
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in January
Start the year off right by investing in these quality businesses. 
Via The Motley Fool
Investing Trends to Follow in 2024
We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2 Biotech Stocks With Huge Catalysts in 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
The Best Stocks to Invest $1,000 in Right Now
It's not too late to get in on these market beaters. 
Via The Motley Fool
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High
Via Investor Brand Network
January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.
These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly. 
Via The Motley Fool
Topics Stocks
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS